JP2019534277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534277A5 JP2019534277A5 JP2019520869A JP2019520869A JP2019534277A5 JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5 JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019520869 A JP2019520869 A JP 2019520869A JP 2019534277 A5 JP2019534277 A5 JP 2019534277A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- acid sequence
- sequence
- antibody construct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162426A JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410054P | 2016-10-19 | 2016-10-19 | |
| US62/410,054 | 2016-10-19 | ||
| US201762549894P | 2017-08-24 | 2017-08-24 | |
| US62/549,894 | 2017-08-24 | ||
| US201762555498P | 2017-09-07 | 2017-09-07 | |
| US62/555,498 | 2017-09-07 | ||
| PCT/US2017/057268 WO2018075692A2 (en) | 2016-10-19 | 2017-10-18 | Antibody constructs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Division JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534277A JP2019534277A (ja) | 2019-11-28 |
| JP2019534277A5 true JP2019534277A5 (enExample) | 2020-11-26 |
| JP7261158B2 JP7261158B2 (ja) | 2023-04-19 |
Family
ID=60452719
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520869A Active JP7261158B2 (ja) | 2016-10-19 | 2017-10-18 | 抗体構築物 |
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162426A Active JP7591015B2 (ja) | 2016-10-19 | 2022-10-07 | 抗体構築物 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180118811A1 (enExample) |
| EP (2) | EP3529269B1 (enExample) |
| JP (2) | JP7261158B2 (enExample) |
| KR (3) | KR20250044934A (enExample) |
| CN (3) | CN118359705A (enExample) |
| AU (1) | AU2017345454B2 (enExample) |
| CA (1) | CA3041254A1 (enExample) |
| DK (1) | DK3529269T3 (enExample) |
| ES (1) | ES3063689T3 (enExample) |
| FI (1) | FI3529269T3 (enExample) |
| IL (2) | IL326918A (enExample) |
| LT (1) | LT3529269T (enExample) |
| MX (1) | MX421186B (enExample) |
| PT (1) | PT3529269T (enExample) |
| WO (1) | WO2018075692A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201704283PA (en) | 2014-11-26 | 2017-06-29 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| JP7058219B2 (ja) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体 |
| MA45255A (fr) | 2016-06-14 | 2019-04-17 | Xencor Inc | Anticorps inhibiteurs de points de contrôle bispécifiques |
| IL326918A (en) * | 2016-10-19 | 2026-05-01 | Invenra Inc | Antibody structures |
| WO2019183406A1 (en) * | 2018-03-21 | 2019-09-26 | Invenra Inc. | Multispecific antibody purification with ch1 resin |
| SG11202009036YA (en) | 2018-03-30 | 2020-10-29 | Merus Nv | Multivalent antibody |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| MX2020010881A (es) | 2018-04-18 | 2020-11-09 | Exelixis Inc | Construcciones de anticuerpos anti-ror. |
| EP3825333A4 (en) * | 2018-07-06 | 2022-04-06 | Abmax Biopharmaceuticals | LOW FUNCTIONALITY ADCC/CDC MONOCLONAL ANTIBODY, METHOD FOR PREPARATION AND USE |
| US20220213225A1 (en) * | 2018-07-30 | 2022-07-07 | Invenra Inc. | Multispecific treg binding molecules |
| CN112996809A (zh) * | 2018-10-10 | 2021-06-18 | 酵活有限公司 | 结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途 |
| EP3902823A1 (en) | 2018-12-24 | 2021-11-03 | Sanofi | Multispecific binding proteins with mutant fab domains |
| JP2023507033A (ja) * | 2019-12-20 | 2023-02-20 | キソジ・バイオテクノロジー・インコーポレイテッド | ポリペプチド、タンパク質複合体及びそれを作製する方法 |
| EP4106805A4 (en) * | 2020-02-20 | 2024-07-03 | Win Therapeutics, Inc. | Bispecific gd2 and b7h2 binding molecules and methods of use |
| KR20230118612A (ko) * | 2020-12-10 | 2023-08-11 | 인벤라 인코포레이티드 | 헤테로다이머화를 위한 직교 돌연변이 |
| WO2023245021A2 (en) * | 2022-06-14 | 2023-12-21 | Invenra Inc. | Multispecific binding agents that target cd25 and/or ctla4 and uses thereof |
| TW202506726A (zh) * | 2023-04-07 | 2025-02-16 | 美商麥迪紐有限責任公司 | 雙特異性工程化抗體 |
| WO2025129132A1 (en) * | 2023-12-14 | 2025-06-19 | Invenra Inc. | Multispecific binding agents that target ctla4 and/or cd25 and uses thereof |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8905551D0 (en) * | 1989-03-10 | 1989-04-19 | Unilever Plc | Detergent compositions |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| ES2544527T3 (es) | 2002-07-31 | 2015-09-01 | Seattle Genetics, Inc. | Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| US20050175619A1 (en) | 2004-02-05 | 2005-08-11 | Robert Duffy | Methods of producing antibody conjugates |
| EP1718667B1 (en) | 2004-02-23 | 2013-01-09 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| GB0514779D0 (en) | 2005-07-19 | 2005-08-24 | Celltech R&D Ltd | Biological products |
| AU2006287416A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Llc | Toxin conjugated Eph receptor antibodies |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| CN101990441A (zh) | 2007-11-28 | 2011-03-23 | 默萨那治疗学股份有限公司 | 生物相容的生物可降解的烟曲霉素类似物轭合物 |
| KR20210049186A (ko) | 2007-11-30 | 2021-05-04 | 애브비 바이오테크놀로지 리미티드 | 단백질 제형 및 이의 제조방법 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| CN102307473A (zh) | 2008-12-10 | 2012-01-04 | 摩萨纳医疗有限公司 | 可生物降解的生物相容性喜树碱-聚合物共轭物的药物制剂 |
| CN102448469A (zh) | 2009-05-28 | 2012-05-09 | 摩萨纳医疗有限公司 | 包括具有可变的释放速率的连接物的聚缩醛(酮)-药物共轭物 |
| EP2437790B1 (en) | 2009-06-03 | 2019-02-20 | Immunogen, Inc. | Conjugation methods |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| CN103458926B (zh) | 2010-11-11 | 2016-10-26 | 艾伯维生物技术有限公司 | 改进的高浓度抗TNF α 抗体液体制剂 |
| KR101962483B1 (ko) * | 2010-11-17 | 2019-03-29 | 추가이 세이야쿠 가부시키가이샤 | 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자 |
| SG193022A1 (en) | 2011-03-10 | 2013-10-30 | Eisai R&D Man Co Ltd | Method for screening for compound capable of enhancing or inhibiting oatp1b1 transport activity, and method for determining expression level of oatp1b1 |
| CA2837840C (en) | 2011-06-10 | 2020-08-04 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| CN103857700A (zh) * | 2011-08-26 | 2014-06-11 | 梅里麦克制药股份有限公司 | 串联fc双特异性抗体 |
| PT2794905T (pt) | 2011-12-20 | 2020-06-30 | Medimmune Llc | Polipéptidos modificados para estrutura de anticorpos bispecíficos |
| DK2838918T3 (da) | 2012-04-20 | 2019-08-12 | Merus Nv | Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler |
| AU2013263002C1 (en) | 2012-05-15 | 2018-05-31 | Seagen Inc. | Self-stabilizing linker conjugates |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| CN104768578A (zh) | 2012-10-25 | 2015-07-08 | 米迪缪尼有限公司 | 稳定的低粘度抗体配制品 |
| CA2892863C (en) | 2012-12-10 | 2022-03-15 | Mersana Therapeutics, Inc. | Polymeric scaffold based on phf for targeted drug delivery |
| EP2931316B1 (en) | 2012-12-12 | 2019-02-20 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| WO2014160360A1 (en) | 2013-03-14 | 2014-10-02 | Mersana Therapeutics Inc. | Tubulysin compounds and conjugates thereof |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| AU2014337555C1 (en) | 2013-10-15 | 2021-01-28 | Seagen Inc. | PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics |
| WO2015095755A1 (en) | 2013-12-19 | 2015-06-25 | Seattle Genetics, Inc. | Methylene carbamate linkers for use with targeted-drug conjugates |
| WO2015123679A1 (en) | 2014-02-17 | 2015-08-20 | Seattle Genetics, Inc. | Hydrophilic antibody-drug conjugates |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| US20170028062A1 (en) | 2014-04-07 | 2017-02-02 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
| WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| TWI551060B (zh) * | 2014-09-24 | 2016-09-21 | 衡宇科技股份有限公司 | Ｂｃｈ解碼方法及其解碼器 |
| JP6904902B2 (ja) * | 2014-12-05 | 2021-07-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ドメイン交換抗体 |
| WO2016180941A1 (en) | 2015-05-13 | 2016-11-17 | Sanofi | Liquid compositions for anti-cd19 antibody-drug conjugates |
| SMT202000004T1 (it) | 2015-07-21 | 2020-03-13 | Immunogen Inc | Metodi di preparazione dei derivati citotossici di benzodiazepina |
| GB2544086B (en) | 2015-11-05 | 2021-04-28 | Povey David | Drip catcher for a stemmed drinking vessel |
| JP2019510741A (ja) | 2016-02-05 | 2019-04-18 | イミュノジェン・インコーポレーテッド | 細胞結合剤・細胞毒性剤コンジュゲートを調製するための効率的なプロセス |
| BR112018068461A2 (pt) | 2016-03-15 | 2019-01-22 | Mersana Therapeutics Inc | conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer. |
| KR102626498B1 (ko) | 2016-03-25 | 2024-01-19 | 씨젠 인크. | 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정 |
| EP3241531A1 (en) * | 2016-05-04 | 2017-11-08 | noonee AG | Leg unit for a wearable sitting posture assisting device |
| IL326918A (en) * | 2016-10-19 | 2026-05-01 | Invenra Inc | Antibody structures |
| WO2019204398A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Trivalent trispecific antibody constructs |
| WO2019204522A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Binding molecules |
| MX2020010881A (es) * | 2018-04-18 | 2020-11-09 | Exelixis Inc | Construcciones de anticuerpos anti-ror. |
| US20220213225A1 (en) * | 2018-07-30 | 2022-07-07 | Invenra Inc. | Multispecific treg binding molecules |
| WO2021145946A1 (en) * | 2020-01-13 | 2021-07-22 | Invenra Inc. | Multispecific treg binding molecules |
-
2017
- 2017-10-18 IL IL326918A patent/IL326918A/en unknown
- 2017-10-18 IL IL266143A patent/IL266143B1/en unknown
- 2017-10-18 CN CN202410343134.7A patent/CN118359705A/zh active Pending
- 2017-10-18 MX MX2019004690A patent/MX421186B/es unknown
- 2017-10-18 CA CA3041254A patent/CA3041254A1/en active Pending
- 2017-10-18 KR KR1020257008855A patent/KR20250044934A/ko active Pending
- 2017-10-18 LT LTEPPCT/US2017/057268T patent/LT3529269T/lt unknown
- 2017-10-18 EP EP17804323.8A patent/EP3529269B1/en active Active
- 2017-10-18 PT PT178043238T patent/PT3529269T/pt unknown
- 2017-10-18 DK DK17804323.8T patent/DK3529269T3/da active
- 2017-10-18 US US15/787,640 patent/US20180118811A1/en not_active Abandoned
- 2017-10-18 ES ES17804323T patent/ES3063689T3/es active Active
- 2017-10-18 EP EP25218239.9A patent/EP4729535A2/en active Pending
- 2017-10-18 KR KR1020197013738A patent/KR102617264B1/ko active Active
- 2017-10-18 CN CN202410332902.9A patent/CN118359704A/zh active Pending
- 2017-10-18 AU AU2017345454A patent/AU2017345454B2/en active Active
- 2017-10-18 KR KR1020237043908A patent/KR20240000650A/ko active Pending
- 2017-10-18 CN CN201780078920.7A patent/CN110177805B/zh active Active
- 2017-10-18 WO PCT/US2017/057268 patent/WO2018075692A2/en not_active Ceased
- 2017-10-18 JP JP2019520869A patent/JP7261158B2/ja active Active
- 2017-10-18 FI FIEP17804323.8T patent/FI3529269T3/fi active
-
2022
- 2022-10-07 JP JP2022162426A patent/JP7591015B2/ja active Active
- 2022-11-15 US US18/055,720 patent/US20240043502A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3529269T3 (fi) | Vasta-ainerakenteita | |
| JP2021522162A5 (enExample) | ||
| JP2021521781A5 (enExample) | ||
| JP2018537966A5 (enExample) | ||
| IL274071B1 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2021530251A5 (enExample) | ||
| JP2023085476A5 (enExample) | ||
| JP2024167313A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| JP2022507487A5 (enExample) | ||
| JP2016536322A5 (enExample) | ||
| JP2020519643A5 (enExample) | ||
| JP2020525032A5 (enExample) | ||
| JP2017534644A5 (enExample) | ||
| JP2017176174A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| RU2015129762A (ru) | ОДНОЛИНКЕРНЫЕ АНТИТЕЛА FabFv И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2017528117A5 (enExample) | ||
| FI3392276T3 (fi) | Heterodimeerimolekyyli, joka perustuu rakenteelliseen CH3-domeeniin, sekä menetelmä sen valmistamiseksi ja sen käyttö | |
| JP2017529067A5 (enExample) | ||
| JP2015146822A5 (enExample) | ||
| JP2017533694A5 (enExample) | ||
| JP2013545455A5 (enExample) | ||
| JP2022512234A5 (enExample) |